Merck Igea Luca Dezzani

FDA Approved Keytruda of Merck for Hodgkin lymphoma

March 14, 2017 Merck has received another FDA approval for Keytruda, and this time for classical Hodgkin lymphoma, marking the PD-1 blocker’s first green-light for use in liquid tumors. Regulators handed out the approval for patients who had already failed at least three therapies. The approval was a first for Merck, but it comes 9 months … Continue reading FDA Approved Keytruda of Merck for Hodgkin lymphoma

Advertisements
Top 10 Pharmaceutical Companies 2017

Top 10 Pharmaceutical Companies 2017

The global pharmaceutical market was estimated in USD 1.1 trillion in 2016. The global market is highly mature and consolidated. The top-10 pharmaceutical companies in this market had share of around 40% in 2016 and approximately 50% considering the top-15. A comparative analysis of the top-15 organizations was used to develop a ranking for these … Continue reading Top 10 Pharmaceutical Companies 2017

U.S. FDA and EMA Accepts Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes, Announced by Merck and Pfizer

March 6, 2017 Merck and Pfizer Inc. have announced that the U.S. Food and Drug Administration (FDA) has accepted for review three New Drug Applications (NDAs) for medicines containing ertugliflozin, an investigational SGLT2 inhibitor in development for helping to improve glycemic control in adults with type 2 diabetes: one for monotherapy, one for the fixed-dose … Continue reading U.S. FDA and EMA Accepts Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes, Announced by Merck and Pfizer

Top Pharma News - IgeaHub

Top Pharma News | February – March 2017

Amgen Announces the Efficay of Repatha® (Evolocumab) for Reducing the Risk of Cardiovascular Events February 2, 2017 Amgen has announced that the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial evaluating whether Repatha® (evolocumab) minimizes the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, … Continue reading Top Pharma News | February – March 2017

World's Most Admired Pharmaceutical Companies 2017

World’s Most Admired Pharmaceutical Companies 2017

Reputation is extremely important for Pharmaceutical Companies. Like every year, Fortune collaborated with Korn Ferry Hay Group on the survey of corporate reputations. To determine the best-regarded companies in 51 industries, Korn Ferry Hay Group evaluated 680 companies in 28 countries. Executives, directors, and analysts have been asked to rate enterprises in their own industry, here … Continue reading World’s Most Admired Pharmaceutical Companies 2017

Merck Igea Luca Dezzani

FDA Accepts Two sBLAs for the KEYTRUDA (pembrolizumab) of Merck for Locally Advanced or Metastatic Urothelial Cancer

February 3, 2017 Merck has announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial cancer, a type of bladder cancer. In particular, the application for first-line use was accepted and granted … Continue reading FDA Accepts Two sBLAs for the KEYTRUDA (pembrolizumab) of Merck for Locally Advanced or Metastatic Urothelial Cancer

Best Pharmaceutical Companies at a Glance: Merck

Best Pharmaceutical Companies at a Glance: Merck

Merck, known as MSD outside the United States and Canada, offers health solutions through its prescription medicines, vaccines, and biologic

Lilly and Merck Expand Immuno-Oncology Collaboration

Jan. 11, 2017 Eli Lilly and Company has announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada, to add a new study of LARTRUVO™ (olaratumab) of Lilly with Merck’s KEYTRUDA® (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma (STS). Especially, the U.S. Food and Drug Administration (FDA) recently approved LARTRUVO … Continue reading Lilly and Merck Expand Immuno-Oncology Collaboration

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma 2016: One Year in Review

Lots of new things happened in the pharmaceutical industry in 2016. At igeahub.com, our mission is to make the pharmaceutical world simple and clear to everyone. We want our readers to have a privileged view on the key player in the healthcare system, and we do our best to keep things simple but highly accurate. The … Continue reading Pharma 2016: One Year in Review

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – November 2016

New Research Details Published by Merck Scientists About the Early Development of Verubecestat November 2, 2016 Merck has announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat. It is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is used … Continue reading Top Pharma News – November 2016